Regulatory agencies require proof of efficacy against specified pathogens before approving label claims. This proof of efficacy is especially important during the current global COVID-19 pandemic.

Element offers GLP and cGMP virology testing options to serve our clients in the antimicrobial and pharmaceutical industries, including disinfectant products tested against SARS-CoV-2 and the U.K. (B.1.1.7) variant, causative agents of COVID-19.

We offer comprehensive virucidal testing services to meet submission requirements for regulatory bodies worldwide (U.S. EPA, Health Canada, TGA, EN and FDA). Our scientists possess years of virology experience, working with a variety of viruses and methods to meet clients’ needs with high-quality results in a timely fashion.

Virology for the Antimicrobial Industry

Element can help you expand your product efficacy claims. Our GLP-compliant virology testing complements our antimicrobial efficacy testing services through additional product tests against common viruses such as Influenza and SARS-CoV-2, the causative agent of COVID-19.

Virology for the Pharmaceutical Industry

Element's cGMP-compliant molecular cell biology and virology testing complements our pharmaceutical lab product testing – particularly in the areas of cell banking and product safety testing. Our testing provides additional peace of mind that your products are free from contamination by organisms such as mycoplasma and cytotoxin, among others.

Viral Library

Our team of over 6,000 Engaged Experts in North America, Europe, The Middle East, Australia, Asia and Africa are ready to help you.